Article ; Online: Potential treatment option of rivaroxaban for breastfeeding women: A case series.
2024 Volume 237, Page(s) 141–144
Abstract: The use of direct oral anticoagulants (DOACs) in breastfeeding women is currently challenging due to limited safety data for breastfeeding infants, and there have been no previous studies on the drug concentration in breastfeeding infants. We treated 2 ... ...
Abstract | The use of direct oral anticoagulants (DOACs) in breastfeeding women is currently challenging due to limited safety data for breastfeeding infants, and there have been no previous studies on the drug concentration in breastfeeding infants. We treated 2 patients (one case was twin pregnancy) with venous thromboembolisms in breastfeeding women administered rivaroxaban at our institution. Blood samples from the mothers and breastmilk samples were collected at time 0 and 2 h after the rivaroxaban administration, breastfeeding was conducted 2 h after the rivaroxaban administration, and blood samples from the infants were collected 2 h after breastfeeding (4 h after maternal rivaroxaban administration). The milk-to-plasma (M:P) ratios were 0.27 in Case 1 and 0.32 in Case 2. The estimated relative infant dose (RID) was 0.82 % in Case 1 Children 1 and 2, and 1.27 % in Case 2. The rivaroxaban concentration in the infant plasma was below the lower limit of quantification in all infants. In addition, even in the high-exposure case simulation based on 5 days of breastfeeding in Case 2, the infant plasma concentration level was below the lower limit of quantification. At 3 months of follow-up, breastfeeding was continued, and all infants grew and developed without any health problems including bleeding events. The current case series showed that there were no pharmacokinetic or clinical concerns for breastfeeding women or breastfed infants, and provides support for rivaroxaban as a safe treatment option for these patients. |
---|---|
MeSH term(s) | Humans ; Rivaroxaban/therapeutic use ; Rivaroxaban/pharmacokinetics ; Female ; Breast Feeding ; Adult ; Factor Xa Inhibitors/therapeutic use ; Factor Xa Inhibitors/pharmacokinetics ; Milk, Human/chemistry ; Milk, Human/metabolism ; Infant ; Venous Thromboembolism/drug therapy ; Infant, Newborn ; Pregnancy |
Chemical Substances | Rivaroxaban (9NDF7JZ4M3) ; Factor Xa Inhibitors |
Language | English |
Publishing date | 2024-04-05 |
Publishing country | United States |
Document type | Case Reports ; Journal Article ; Letter |
ZDB-ID | 121852-9 |
ISSN | 1879-2472 ; 0049-3848 |
ISSN (online) | 1879-2472 |
ISSN | 0049-3848 |
DOI | 10.1016/j.thromres.2024.04.003 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 863: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.